We are delighted to announce that our seminal paper A novel process driving Alzheimer’s validated in a mouse model: therapeutic potential’ has been accepted by the peer-reviewed journal Alzheimer’s & Dementia: Translational Research & Clinical Interventions. At last, our disruptive approach to Alzheimer’s, proof of concept of our basic hypothesis, and efficacy of our novel drug NBP14, will have a wider public platform. We see this MS as a real milestone since it brings together previously disparate reports in the literature for mapping the steps in the neurodegenerative process and suggests a first-in-class drug treatment, now acknowledged by the MHRA as completely innovative. Although the manuscript is under embargo for 6 weeks, we are currently planning a press conference in early April. More details will be available as plans become clearer, but please watch this space!
LATEST NEWS
- Baroness Greenfield to attend NeuRA (Neuroscience Research Australia) Sydney in May 2024!
- Baroness Greenfield to speak at the Early Career Dementia Researchers Retreat in June 2024!
- Transforming Alzheimer’s Disease Detection – Collaboration with Aptamer Group
- THENA Capital podcast with Baroness Susan Greenfield
- Neuro-Bio and Aptamer enter the second phase of Alzheimer’s test development